Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Senthil Selvaraj

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
JAMA|May 12, 2024
Cardiovascular Burden of the V142I Transthyretin VariantSenthil Selvaraj, Brian Claggett, Svati H Shah, et al.
JACC. Basic to Translational Science|March 26, 2025
Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEFSenthil Selvaraj, Lydia Coulter Kwee, Elizabeth J Thompson, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
JACC. Cardiovascular Imaging|September 20, 2020
Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection FractionSenthil Selvaraj, Jessica Kim, Bilal A Ansari, et al.
JACC. Heart Failure|April 17, 2025
Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Antoneta Karaj, Julio A Chirinos, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
JAMA|May 12, 2024
Cardiovascular Burden of the V142I Transthyretin VariantSenthil Selvaraj, Brian Claggett, Svati H Shah, et al.
JACC. Basic to Translational Science|March 26, 2025
Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEFSenthil Selvaraj, Lydia Coulter Kwee, Elizabeth J Thompson, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
JACC. Cardiovascular Imaging|September 20, 2020
Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection FractionSenthil Selvaraj, Jessica Kim, Bilal A Ansari, et al.
JACC. Heart Failure|April 17, 2025
Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Antoneta Karaj, Julio A Chirinos, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Pageof 12